Stock Down 69% in Pre-Market Trading
- Fulcrum Therapeutics shares drop after trial failure
- Losmapimod fails to meet primary endpoint for facioscapulohumeral muscular dystrophy treatment
- Stock down 69% in premarket trading
- Company suspends losmapimod program in facioscapulohumeral muscular dystrophy
Fulcrum Therapeutics’ shares plunged after the company announced that its Phase 3 trial for losmapimod as a treatment for facioscapulohumeral muscular dystrophy failed to meet its primary endpoint, leading to a 69% drop in stock price. The clinical-stage biopharmaceutical firm reported that the trial did not show improvement in relative surface area or ‘reachable workspace’ in patients with the condition compared to a placebo. As a result, CEO Alex Sapir plans to suspend the losmapimod program for facioscapulohumeral muscular dystrophy.
Factuality Level: 10
Factuality Justification: The article provides accurate information about the trial’s failure to achieve its primary endpoint and secondary endpoints, the stock’s decline, and the company’s response to the results.
Noise Level: 2
Noise Justification: The article provides relevant information about a specific event in the biopharmaceutical industry, with no irrelevant or misleading content. It reports on the results of a clinical trial and the company’s response to those results without diving into unrelated topics. The article also supports its claims with evidence (the trial results) and provides actionable insights for investors by indicating that the company plans to suspend the losmapimod program in facioscapulohumeral muscular dystrophy.
Public Companies: Fulcrum Therapeutics (FULC)
Key People: Alex Sapir (Chief Executive)
Financial Relevance: Yes
Financial Markets Impacted: Biotech and pharmaceutical industry
Financial Rating Justification: The article discusses the impact of a clinical trial failure on Fulcrum Therapeutics’ stock price, which is relevant to financial markets in the biotech and pharmaceutical industry.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event in the text and it’s not related to a financial crisis either.
Move Size: 69%
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.marketwatch.com 
